Monoclonal antibodies

Lecanemab
#Alzheimer's #Biogen #Eisai #European Commission #Monoclonal antibodies #Neuroscience

Lecanemab gets EU approval in early Alzheimer’s

The European Commission (EC) has granted Leqembi (lecanemab) Marketing Authorisation (MA) in the European Union (EU).  The approval makes the medicine the first therapy that targets an underlying cause of Alzheimer’s disease (AD) to be granted a MA in the EU.  Lecanemab is indicated for the treatment of adult patients… Read More

#News #Regulatory #Trending News

#3D modelling #Artificial intelligence (AI) #European Commission #Monoclonal antibodies #Oncology #Solid tumours

This week in drug discovery (7-11 April) 

News round-up for 7-11 April by DDW Senior Digital Content Editor Diana Spencer. As the political news brings more uncertainty for the sector, this week we are focusing on positive developments in the field of oncology, from the possibilities of cancer cures in the rainforest, to a new… Read More

#News

European Commission
#European Commission #Johnson & Johnson #Monoclonal antibodies #Oncology

EC approves subcutaneous use of J&J antibodies for cancer

The European Commission (EC) has approved an indication extension for two of Johnson & Johnson’s monoclonal antibody therapies in oncology.  The approval of Darzalex (daratumumab) has been extended to include a subcutaneous (SC) formulation in the frontline setting in combination with bortezomib, lenalidomide, and dexamethasone (daratumumab-VRd) for newly diagnosed multiple… Read More

#News #Regulatory

#Alzheimer's #Antibody drug conjugate (ADC) #hepatitis #Monoclonal antibodies #Oncology #Therapeutic Antibodies

This week in drug discovery (31 March – 4 April) 

News round-up for 31 March – 4 April by DDW Senior Digital Content Editor Diana Spencer. The headlines this week have demonstrated the importance of antibody therapies, particularly in treating cancer, but also as potential therapeutics for a range of other diseases including hepatitis D and Alzheimer’s. Read More

#News

Therapeutic antibodies
#Alzheimer's #Antibodies #Cancer #Covid-19 #Engineered antibodies #Immunology #Janssen #Monoclonal antibodies #Rare disease #Therapeutic Antibodies

Podcast: Where is the innovation in the therapeutic antibody market?

This is the latest episode of the free DDW narrated podcast, titled “Where is the innovation in the therapeutic antibody market?”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Finding the North Star of therapeutic antibodies” and “Which diseases… Read More

#News

Bladder cancer
#AstraZeneca #Bladder cancer #FDA #Monoclonal antibodies #Oncology

Imfinzi approval a ‘breakthrough’ for muscle-invasive bladder cancer

AstraZeneca’s Imfinzi (durvalumab) has been approved by the US Food and Drug Administration (FDA) for the treatment of adult patients with muscle-invasive bladder cancer (MIBC).  It is approved in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery to remove the bladder). … Read More

#News #Regulatory

Monoclonal antibody
#Bluejay Therapeutics #Clinical trial #hepatitis #Monoclonal antibodies #Viral hepatitis

Trial investigates monoclonal antibody for chronic hepatitis D

Bluejay Therapeutics’ AZURE-1 global pivotal clinical trial evaluating brelovitug (BJT-778) for the treatment of chronic hepatitis D (CHD) has dosed its first patient.   Brelovitug is an investigational fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets the surface antigen (anti-HBsAg) on both the hepatitis D virus… Read More

#News

#Helicore Biopharma #Monoclonal antibodies #Obesity #Phase I trial #Weight loss

First-in-class GIP antagonist for obesity enters Phase I trials

Helicore Biopharma has reported dosing the first participant in its Phase I study of HCR-188 for the treatment of obesity.   HCR-188 is a first-in-class monoclonal antibody (mAb) designed to bind to circulating glucose-dependent insulinotropic peptide (GIP) ligand, unlike antibodies that bind the GIP receptor (GIP… Read More

#News

Bispecific antibodies
#Antibodies #Bispecific Antibodies #Monoclonal antibodies #Therapeutic Antibodies

Download the Article: The discovery and evolution of antibody formats

As antibody therapeutics evolve, new formats such as bispecific antibodies (bsAbs) and Fab fragments offer new and exciting therapeutic opportunities. However, traditional mAb isolation methods are often ineffective, necessitating innovative solutions. This Article explores these challenges and introduces Astrea Bioseparations’ Fabsorbent F1P HF as an alternative strategy for isolating… Read More

#News

Ki67 staining
#Antibody drug conjugate (ADC) #Biospecimen collection #Monoclonal antibodies #Oncology

Advancing cancer therapy with antibody-drug conjugates

Cathie Miller, PhD, Senior Director of Product Marketing at BioIVT, discusses biospecimens and analytical techniques supporting the rapid evolution of ADCs in oncology. Antibody-drug conjugates (ADCs) are making significant strides forward as targeted cancer therapies. By coupling the specificity of antibodies with the potency of cytotoxic drugs, ADCs aim to… Read More

#Cancer Research #Exclusive Content

#Antibodies #Bispecific Antibodies #Monoclonal antibodies #Therapeutic Antibodies

The Discovery and Evolution of Antibody Formats

As antibody therapeutics evolve, new formats such as bispecific antibodies (bsAbs) and Fab fragments offer new and exciting therapeutic opportunities. However, traditional mAb isolation methods are often ineffective, necessitating innovative solutions. This article explores these challenges and introduces Astrea Bioseparations’ Fabsorbent™ F1P HF as an alternative strategy for isolating next-generation… Read More

#Resources

Drugs targeting amyloid Plaque
#Alzheimer's #Drug safety #Eisai #Monoclonal antibodies #National Institute for Health and Care Excellence (NICE)

Researchers call for extra safety monitoring of lecanemab

Researchers from the UK’s Drug Safety Research Unit are calling for the robust monitoring of the safety of lecanemab, a new drug to treat Alzheimer’s disease (AD).  In a review article, published in the British Journal for Clinical Pharmacology, the researchers discuss the need for ongoing assessment of the safety… Read More

#News #Regulatory #Trending News

#Antibodies #Monoclonal antibodies #Pandemic prevention #Pandemic response

Polyclonal and recombinant antibody development

Joerg Schuettrumpf, Chief Scientific Innovation Officer at Grifols, discusses advancements in antibody therapies, focusing on IgA, IgM, and recombinant polyclonal technologies to enhance treatment efficacy, scalability, and preparedness for global health challenges. IgA and IgM therapies The therapeutic antibody field is progressing rapidly, says Schuettrumpf, with key advances in broad-spectrum… Read More

#Exclusive Content

Monoclonal antibodies
#Inflammatory Bowel Disease #Monoclonal antibodies #Phase II trial #Sanofi #Teva

New data indicate duvakitug could “transform” IBD treatment

Sanofi and Teva Pharmaceuticals have revealed new results from their Phase IIb study of duvakitug for ulcerative colitis (UC) and Crohn’s disease (CD), the two most common forms of inflammatory bowel disease (IBD).   The results were shared in two oral presentations at the 20th Congress of the… Read More

#News #Trending News

Monoclonal antibody
#Dermatology #FDA #Monoclonal antibodies #Orphan drugs #Rare disease

Dupixent for bullous pemphigoid under FDA priority review

The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP).  The sBLA is supported by data from a pivotal study evaluating the efficacy and safety of Dupixent in 106 adults with moderate-to-severe… Read More

#News #Regulatory

Monoclonal antibodies
#CSL #European Commission #Monoclonal antibodies #Rare disease

EC approves antibody to prevent hereditary angioedema attacks

The European Commission (EC) has approved Andembry (garadacimab), the only once-monthly treatment targeting factor XIIa to prevent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older.  Andembry inhibits plasma protein factor XIIa, which initiates the cascade of events leading to angioedema at various sites… Read More

#News #Regulatory